Stock Code: 1788

Hi-Clearance Inc. and Subsidiaries

Consolidated Financial Statements and Independent Auditors' Report

For the Six Months Ended June 30, 2024 and 2023

Company Address: 8F.-2, No. 2, Ln. 609, Sec. 5, Chongxin Rd., Sanchong Dist., New Taipei City Telephone: (02)2995-3318

Table of Contents

			Item	Page			
I.	Cover	Page		1			
II.	I. Table of Contents						
III.	III. Independent Auditors' Report						
IV.	Conso	lidat	ed Balance Sheets	5			
V.	Conso	lidat	ed Statements of Comprehensive Income	6			
VI.	Conso	lidat	ed Statements of Changes in Equity	7			
VII.	Conso	lidat	ed Statements of Cash Flows	8			
VIII	.Notes	to Co	onsolidated Financial Statements				
	(I)	Con	npany History	9			
	(II)		e of Authorization for Issuance of the Parent Company Only ancial Statements and Procedures for Authorization	9			
	(III)	App	lication of New and Amended Standards and Interpretations	9-11			
	(IV) Summary of Significant Accounting Policies						
	(V) Primary Sources of Uncertainties in Material Accounting Judgments, Estimates, and Assumptions						
	(VI) Details of Significant Accounts						
	(VII)	Rela	ated Party Transactions	37-38			
	(VIII)	Plec	lged Assets	38-39			
	(IX) Significant Contingent Liabilities and Unrecognized Contract Commitments						
	(X)	Sigr	nificant Disaster Loss	39			
	(XI) Significant Events after the Balance Sheet Date(XII) Others						
	(XIII) Supplementary Disclosures						
		1.	Information on Significant Transactions	40-43			
		2.	Information on Invested Companies	43			
		3.	Information on Investments in Mainland China	43-44			
		4.	Information on Major Shareholders	45			
	(XIV)	Seg	ment Information	45-46			

Independent Auditors' Report

Board of Directors of Hi-Clearance Inc. herein declares:

Introduction

The consolidated balance sheets of Hi-Clearance Inc. and its subsidiaries as of June 30, 2024 and June 30, 2023, and the consolidated statements of comprehensive income for the periods from April 1 to June 30, 2024 and 2023, and from January 1 to June 30, 2024 and 2023, as well as the consolidated statements of changes in equity and consolidated cash flow statements for the periods from January 1 to June 30, 2024 and 2023, and the accompanying notes to the consolidated financial statements (including a summary of significant accounting policies), have been reviewed and completed. In accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, as approved and published by the Financial Supervisory Commission, the management is responsible for preparing the interim financial statements in accordance with IAS 34, Interim Financial Reporting. The auditors are responsible for forming a conclusion on the consolidated financial statements based on the review results.

Scope

In addition to the introductory paragraph that provides a summary of the conclusion, the auditor performed the review work in compliance with TWSRE2410 "Review of Financial Statements." The procedures conducted during the review of the consolidated financial statements involve making inquiries (mainly to personnel responsible for financial and accounting matters), performing analytical procedures, and conducting other review procedures. The scope of review work is clearly smaller than that of audit work, so the auditor may not be able to detect all significant matters that can be identified through an audit, and therefore cannot express an audit opinion.

Basis for Retaining Conclusions

As described in Note 4 (II) to the consolidated financial statements, certain non-material subsidiaries included in the aforementioned consolidated financial reports are based on the unaudited financial statements of those investee companies for the same periods. As of June 30, 2024 and June 30, 2023, the total assets of these non-material subsidiaries were NT\$687,734 thousand and NT\$604,816 thousand, respectively, accounting for 13.74% and 13.36% of the consolidated total assets. Their total liabilities were NT\$284,159 thousand and NT\$256,467 thousand, respectively, accounting for 13.36% and 14.98% of the consolidated total liabilities. The comprehensive income for the periods from April 1 to June 30, 2024 and 2023, and from January 1 to June 30, 2024 and 2023 was NT\$7,420 thousand, NT\$2,279 thousand, NT\$14,502 thousand, and NT\$9,421 thousand, respectively, accounting for 6.74%, 2.48%, 6.99%, and 5.31% of the consolidated comprehensive income.

Except for the items described in the previous paragraph, as noted in Note 6 (VI) to the consolidated financial statements, the investments in associates of Hi-Clearance Inc. and its subsidiaries, accounted for using the equity method, were NT\$120,340 thousand and NT\$112,430 thousand as of June 30, 2024 and June 30, 2023, respectively. For the periods from April 1 to June 30, 2024 and 2023, and from January 1 to June 30, 2024 and 2023, the share of profit or loss from associates accounted for using the equity method was NT\$3,877 thousand, NT\$1,348 thousand, NT\$8,224 thousand, and NT\$5,997 thousand, respectively. These amounts are based on the unaudited financial statements of the investee companies for the same periods.

Retaining Conclusions

According to the results of our review, except for the potential adjustments that may affect the consolidated financial statements if the financial reports of the investee companies were audited, we have not found any instances where the consolidated financial statements do not comply with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Accounting Standard 34 "Interim Financial Reporting," as recognized and issued by the Financial Supervisory Commission, in all material respects. Therefore, the consolidated financial position of Hi-Clearance Inc. and its subsidiaries as of June 30, 2024 and June 30, 2023, and the consolidated financial performance for the periods from April 1 to June 30, 2024 and 2023, and from January 1 to June 30, 2024 and 2023, are fairly presented.

KPMG Taiwan

CPA:

Securities authorities approval document no.:	Jin-Guan-Zheng-Shen-Zi No. : 1040003949
August 2, 2024	Tai-Cai-Zheng-Liu-Zi No.0920122026

Hi-Clearance Inc. and Subsidiaries

Consolidated Balance Sheets

June 30, 2024, December 31, 2023, and June 30, 2023

			2024.6.30		2023.12.31	l	2023.6.30	
	Assets	A	mount	%	Amount	%	Amount	%
	Current assets:							
1100	Cash and cash equivalents (Note 6 (I))	\$	427,141	9	401,137	9	469,322	10
1110	Financial assets at fair value through profit or loss - current							
	(Note 6 (II))		53,167	1	51,966	1	51,420	1
1150	Net amount of notes receivable (Notes 6 (IV), (XX) and Note 8)		193,007	4	229,978	5	176,663	4
1170	Net amount of accounts receivable (Notes 6 (IV), (XX))		1,042,131	21	919,622	20	912,027	20
1180	Net amount of accounts receivable - related parties (Notes 6 (IV), (XX) and Note 7)		71,570	1	85,080	2	104,282	2
1197	Net amount of financial leases receivable (Notes 6 (IV), (XX))		38,444	1	39,337	1	41,281	1
1200	Other receivables		14,434	-	1,341	-	24,218	1
1300	Inventory (Note 6 (V))		621,983	12	645,457	14	586,494	13
1410	Prepayments		31,380	1	69,183	1	36,719	1
1476	Other financial assets - current (Note 8)		57,261	1	58,895	1	50,402	1
1479	Other current assets - others		7,461	-	7,892	-	7,257	-
	Total current assets		2,557,979	51	2,509,888	54	2,460,085	54
	Non-current assets:							
1517	Financial assets at fair value through other comprehensive							
	income - non-current (Note 6 (III))		45,268	1	268	-	268	-
1550	Investments accounted for using the equity method (Note 6 (VI))		120,340	2	116,390	3	112,430	3
1600	Property, plant, and equipment (Notes 6 (VII) and 8)		1,096,766	22	1,061,550	23	1,058,533	23
1755	Right-of-use assets (Note 6 (VIII))		579,050	12	519,455	11	488,157	11
1760	Investment property (Note 6 (IX))		26,096	1	26,101	1	26,106	1
1780	Intangible assets (Note 6 (X))		180,699	3	188,979	4	195,770	2
1840	Deferred income tax assets		4,917	-	4,917	-	14,699	-
1930	Long-term notes receivable (Notes 6 (IV), (XX) and Note 8))	7,858	-	7,168	-	5,908	-
194D	Net amount of long-term financial leases receivable (Notes 6 (IV), (XX))		93,481	2	96,086	2	95,968	2
1990	Other non-current assets - others (Note 13 (I))		294,490	6	87,083	2	70,535	2
	Total non-current assets		2,448,965	49	2,107,997	46	2,068,374	46

Liabilities and equity
Current liabilities:
Short-term loans (Note 6 (XI) and Note 8)
Financial liabilities at fair value through profit or loss -
current (Note 6 (II))
Contract liabilities - current (Note 6 (XX))
Notes payable
Accounts payable
Accounts payable - related parties (Note 7)
Dividends payable
Other payables - others
Other payables - related parties (Note 7)
Current income tax liabilities
Lease liabilities - current (Note 6 (XIII))
Other current liabilities
Total current liabilities
Non-current liabilities:
Contract liabilities - non-current (Note 6 (XX))
Long-term loans (Note 6 (XII))
Deferred income tax liabilities
Lease liabilities - non-current (Note 6 (XIII))
Other non-current liabilities
Total non-current liabilities
Total liabilities
Equity (Note XVII):
Capital stock
Capital surplus
Retained earnings
Other equity
Total equity
Total liabilities and equity

Total assets

<u>\$ 5,006,944 100 4,617,885 100 4,528,459 100</u>

Unit: NT\$ thousand

2024.6.30		2023.12.31	l	2023.6.30	
Amount	%	Amount	%	Amount	%
\$ 317,987	6	91,565	2	81,565	2
-	-	240	-	-	-
18,089	-	13,920	-	12,138	-
7,651	-	7,521	-	7,152	-
600,331	13	681,169	15	549,843	12
2,293	-	2,282	-	1,873	-
311,647	6	-	-	311,647	7
154,667	3	184,597	4	143,195	3
9,353	-	14,665	-	7,082	-
48,682	1	29,218	1	32,276	1
77,290	2	71,364	2	66,349	2
20,091	-	26,516	1	15,778	-
 1,568,081	31	1,123,057	25	1,228,898	27
24,027	_	18,713	_	16,887	1
-	_	12,357	_	13,119	- 1
8,372	_	8,372	_	8,079	-
525,112	11	469,455	10	442,587	10
1,770	-	2,063	-	2,478	-
 559,281	11	510,960	10	483,150	11
2,127,362	42	1,634,017	35	1,712,048	38
445,210	9	445,210	10	445,210	10
1,601,988	32	1,601,988	35	1,601,960	35
837,479	17	943,984	20	774,107	17
 (5,095)	-	(7,314)	-	(4,866)	-
 2,879,582	58	2,983,868	65	2,816,411	62
\$ 5.006.944	100	4.617.885	100	4.528.459	100

Hi-Clearance Inc. and Subsidiaries

Consolidated Statements of Comprehensive Income

April 1 to June 30, 2024, and 2023, and January 1 to June 30, 2024, and 2023

Unit: NT\$ thousand

		April to Jun 2024	ne	April to Ju 2023	ine	January to 3 2024	June	January to J 2023	June
	_	Amount	%	Amount	%	Amount	%	Amount	%
4000	Operating revenue (Notes 6 (XIII), (XX) and Note 7) \$	1,096,986	100	956,200	100	2,061,829	100	1,929,179	100
5000	Operating costs (Notes 6 (V), (XV), Note 7, and Note _ 12)	801,425	73	699,554	73	1,508,375	73	1,425,920	74
	Gross profit	295,561	27	256,646	27	553,454	27	503,259	26
	Operating expenses (Notes 6 (IV), (XV), Note 7, and Note 12):								
6100	Selling and marketing expenses	102,705	9	81,629	9	189,454	9	164,673	9
6200	General and administrative expenses	72,750	7	76,358	8	138,666	7	138,988	7
6450	Expected credit losses (or reversal)	(93)	-	3,919	-	(431)	-	5,367	-
	Total operating expenses	175,362	16	161,906	17	327,689	16	309,028	16
	Net operating income	120,199	11	94,740	10	225,765	11	194,231	10
	Non-operating income and expenses:								
7100	Interest income (Note 6 (XXII))	2,925	-	3,812	-	5,008	-	6,047	-
7010	Other income (Note 6 (XXII) and Note 7)	4,999	-	2,071	-	10,551	1	3,636	-
7020	Other gains and losses (Note 6 (XXII))	6,003	1	4,710	1	9,662	-	7,261	-
7050	Financial costs (Notes (XIII) and (XXII))	(2,853)	-	(3,558)	-	(5,360)	-	(7,448)	-
7060	Share of profit or loss of affiliates and joint ventures								
	accounted for using the equity method (Note 6								
	(VI))	3,877	-	1,348	-	8,224	-	5,997	-
	Total non-operating income and expenses	14,951	1	8,383	1	28,085	1	15,493	-
7900	Income before tax	135,150	12	103,123	11	253,850	12	209,724	10
7950	Deduction: Income tax expenses (Note 6 (XVI))	26,111	2	10,895	1	48,708	2	32,198	2
	Net income for the period	109,039	10	92,228	10	205,142	10	177,526	8
8300	Other comprehensive income:								
8360	Components that may be reclassified to profit or loss								
8361	Exchange differences on translation of financial	1,012	-	(338)	-	2,219	-	(90)	-
	statements of foreign operations								
	Total components that may be reclassified to _	1,012	-	(338)	-	2,219	-	(90)	_
	profit or loss								
8300	Other comprehensive income (net after tax)	1,012	-	(338)	-	2,219	-	(90)	-
	Total comprehensive income for the period	110,051	10	91,890	10	207,361	10	177,436	8
	Earnings per share (NT\$) (Note 6 (XIX))					i			
9750	Basic earnings per share (NT\$)		2.45		2.08		4.61		4.19
9850	Diluted earnings per share (NT\$)		2.45		2.08		4.60		4.17

(Please refer to the notes of the Consolidated Financial Statements)

Chairman: Lee Chung-Liang

Executive: Chen Kuo-Shih Chief Accountant: Chang Yaw-Yuan

Hi-Clearance Inc. and Subsidiaries Consolidated Statements of Changes in Equity January 1 to June 30, 2024, and 2023

Unit: NT\$ thousand

				Retaine	d Earnings		Other Equi Exchange Differences	ty Items	
Capital Stock - Common Shares		Capital Surplus	Legal Reserve	Special Reserve	Unappropriated Earnings	Total	on Translation of Financial Statements of Foreign Operations	Others	Total Equity
\$	405,210	1,130,866	362,933	5,569	539,726	908,228	(4,776)	-	2,439,528
	-	-	37,389	- (793)	(37,389) 793	-	-	-	-
	-	-	-		(311,647) 177,526	- (311,647) 177,526	-	-	(311,647) 177,526
	-	-	-	-	-	-	(90)	-	(90)
		-	-	-	177,526	177,526	(90)	-	177,436
	40,000	458,750 12,344	-	-	-	-	-	-	498,750 12,344
\$	445,210	1,601,960	400,322	4,776	369,009	774,107	(4,866)	-	2,816,411
\$	445,210	1,601,988	400,322	4,776	538,886	943,984	(6,645)	(669)	2,983,868
	-	-	34,740	-	(34,740)	-	-	-	-
	-	-	-	1,869	(1,869)	-	-	-	-
	-	-	-	-	(311,647)	(311,647)	-	-	(311,647)
	-	-	-	-	205,142	205,142	-	-	205,142
	-	-		-		- 205,142	<u>2,219</u> 2,219	-	2,219
\$	- 445,210	- 1,601,988	- 435,062	- 6,645	205,142 395,772	<u>837,479</u>	<u>(4,426)</u>	- (669)	207,361 2,879,582

(Please refer to the notes of the Consolidated Financial Statements)

Executive: Chen Kuo-Shih

Balance as of January 1, 2023

Net income for the period

Cash capital increase

Appropriation of legal reserve Reversal of special reserve

Share-based payment transactions Balance as of June 30, 2023 Balance as of January 1, 2024

Appropriation of legal reserve Appropriation of special reserve Cash dividends of common shares

Net income for the period

Balance as of June 30, 2024

Cash dividends of common shares

Appropriation and distribution of earnings:

Other comprehensive income for the period Total comprehensive income for the period

Appropriation and distribution of earnings:

Other comprehensive income for the period Total comprehensive income for the period

Hi-Clearance Inc. and Subsidiaries Consolidated Statements of Cash Flows January 1 to June 30, 2024, and 2023

Unit: NT\$ thousand

	January to June 2024	January to June 2023
Cash flows from operating activities:	¢	200 524
Income before tax for the period Adjustment items:	<u>\$ 253,850</u>	209,724
Adjustments to reconcile profit (loss)		
Depreciation expenses	79,618	75,003
Amortization expenses	8,280	6,792
Expected credit (or reversal) losses	(431)	5,367
Net gain on financial assets and liabilities at fair value through profit or loss	(2,343)	(290)
Interest expenses Interest income	5,360 (5,008)	7,448 (6,047)
Share-based remuneration cost	-	12,344
Share of profit of associates and joint ventures accounted for using the equity method	(8,224)	(5,997)
Gain on disposal of property, plant, and equipment	(1,094)	(460)
Gains on lease modifications	(449)	-
Total adjustments to reconcile profit (loss)	75,709	94,160
Changes in operating assets and liabilities: Decrease in financial assets at fair value through profit or loss	921	68
Decrease in notes receivable	36,602	35,705
Increase in accounts receivable and financial leases	(118,923)	(60,214)
Decrease in accounts receivable - related parties	13,510	10,224
Increase in other receivables	(13,093)	(18,093)
Decrease (increase) in inventory	(7,471)	131,943
Decrease in prepayments	37,803	2,417
Decrease (increase) in other current assets	431 1,634	(2,721)
Decrease (increase) in other financial assets Increase in other operating assets	(7,552)	(8,137) (403)
Total net changes in assets related to operating activities	(56,138)	90,789
Decrease in financial liabilities at fair value through profit or loss	(19)	(489)
Increase in contractual liabilities	9,483	2,786
Increase (decrease) in notes payable	130	(473)
Decrease in accounts payable	(80,838)	(149,945)
Increase in payables to related parties	(20.020)	561
Decrease in other payables Decrease in other payables - related parties	(29,930) (5,312)	(52,873) (14,830)
Decrease in other current liabilities	(6,425)	(14,850) (265)
Decrease in net defined benefit liabilities	(133)	(4,800)
Total net changes in liabilities related to operating activities	(113,033)	(220,328)
Total net changes in assets and liabilities related to operating activities	(169,171)	(129,539)
Total adjustment items	(93,462)	(35,379)
Cash inflows from operations Interest received	160,388 5,008	174,345 6,047
Interest paid	(5,360)	(7,448)
Income tax paid	(29,244)	(52,600)
Net cash inflow from operating activities	130,792	120,344
Cash flows from investing activities:		
Acquisition of financial assets at fair value through other comprehensive income	(45,000)	-
Acquisition of property, plant, and equipment	(26,454)	(17,373)
Disposal of property, plant, and equipment Increase in refundable deposits	2,566 (34,740)	729 (20,428)
Decrease in refundable deposits	26,107	18,248
Intangible asset acquisition	-	(2,381)
Increase in prepayments for equipment and land	(211,355)	(8,221)
Dividends received from associates	4,274	4,289
Net cash outflow from investing activities	(284,602)	(25,137)
Cash flows from financing activities: Increase in short-term loans	(00.000	960.000
Decrease in short-term loans	680,000 (453,578)	860,000 (1,273,767)
Repayments of long-term loans	(12,651)	-
Increase in guarantee deposits received	6,054	-
Decrease in guarantee deposits received	(6,214)	-
Lease principal payment	(36,047)	(35,212)
Cash capital increase	-	498,750
Net cash inflow from financing activities	177,564	49,771
Effects of exchange rate changes on the balance of cash held in foreign currencies Increase in cash and cash equivalents during the period	<u> </u>	<u> </u>
Cash and cash equivalents at beginning of period	401,137	324,220
Cash and cash equivalents at end of period	\$ 427,141	469,322

(Please refer to the notes of the Consolidated Financial Statements)

Chairman: Lee Chung-Liang

Executive: Chen Kuo-Shih

Chief Accountant: Chang Yaw-Yuan

Hi-Clearance Inc. and Subsidiaries Notes to Consolidated Financial Statements For the Six Months Ended June 30, 2024 and 2023 (Unless otherwise specified, all amounts are in NT\$ thousand)

I. Company History

Hi-Clearance Inc. (hereinafter referred to as "the Company") was established on February 13, 1989, with the approval of the Ministry of Economic Affairs. The Company's registered address is 8F.-2, No. 2, Ln. 609, Sec. 5, Chongxin Rd., Sanchong Dist., New Taipei City, Taiwan (R.O.C.) Primary business activities of the Company and its subsidiaries (the Consolidated Companies) involve trading medical equipment, biochemical reagents, and Western medicine, as well as providing medical management consulting services.

II. Date of Authorization for Issuance of the Parent Company Only Financial Statements and Procedures for Authorization

The Consolidated Financial Statements have been approved for release by the Board of Directors on August 2, 2024.

III. Application of New and Amended Standards and Interpretations

(I) The impact of adopting the newly issued and revised criteria and interpretations approved by the Financial Supervisory Commission

Since January 1, 2024, the Consolidated Companies have been implementing the newly revised International Financial Reporting Standards (IFRSs), which has not significantly impacted the Consolidated Financial Statements.

- Amendments to IAS 1 "Classify Liabilities as Current or Non-current"
- Amendments to IAS 1 "Non-current Liabilities with Covenants"
- Amendments IAS 7 and IFRS 7 "Supplier Finance Arrangements"
- Amendments to IFRS 16 "Lease Liabilities in Sale and Leaseback Transactions"
- (II) Impact of IFRSs not yet recognized by the FSC

The Consolidated Companies assessed that the application of the following newly revised IFRSs, effective January 1, 2025, would not have a material impact on the Consolidated Financial Statements.

- Amendments to IAS 21 "Lack of Exchangeability"
- (III) New and amended standards and interpretations not yet recognized by FSC

The International Accounting Standards Board has issued and revised standards and interpretations that have not yet been approved by the Financial Supervisory Commission. The following are the ones that may be relevant to the Consolidated Companies:

New or Amended Standards	Main Content for Amendments	Effective Date of Issuance by the IASB
IFRS 18 "Presentation and Disclosure in Financial Statements"	The new standards introduce three categories of income and expenses, two subtotals on the income statement, and a single note regarding management performance measurement. These three amendments and enhancements to the guidance on segmenting information in financial statements lay the foundation for providing users with improved and consistent information, and will have an	January 1, 2027
IFRS 18 "Presentation and Disclosure in Financial Statements"	 impact on all companies. A more structured income statement: The company currently uses various formats to express its financial performance, which makes it challenging for investors to compare the financial performance of different companies. The new standards have implemented a more structured income statement. They have introduced a new subtotal called "operating profit" and require that all revenues and expenses be classified into three new categories based on the company's main business activities. 	January 1, 2027
	• Management Performance Measures (MPM): The new criteria introduce the concept of management performance measures. Companies are now required to provide an explanation, in a single note in the financial statements, regarding the usefulness of each measurement indicator, its calculation method, and how it is adjusted for amounts recognized in accordance with international financial reporting standards and accounting principles.	
	• More detailed information: The new standards provide instructions on how companies can improve the organization of information in financial statements. This guidance includes determining whether the information should be included in the primary financial statements or further detailed in the notes.	

The Consolidated Companies is currently assessing the effects of the aforementioned criteria and interpretations on its financial condition and operating results. The relevant findings will be disclosed once the evaluation is complete.

The Consolidated Companies do not expect the following new releases and amendments to standards, that have yet to be endorsed by the FSC, to have a material impact on the Consolidated Financial Statements.

- Amendments to IFRS 10 and IAS 28 "Sale or Contribution of Assets between an Investor and Its Associate or Joint Venture"
- IFRS 17 "Insurance Contracts" and amendments to IFRS 17
- IFRS 19 "Subsidiaries without Public Accountability: Disclosures"
- Amendments to IFRS 9 and IFRS 7, "Amendments to the Classification and Measurement of Financial Instruments"
- Annual improvements to IFRS

IV. Summary of Significant Accounting Policies

Significant accounting policies adopted in the Consolidated Financial Statements: Unless stated otherwise, the following accounting policies have been applicable for all reporting periods of this Consolidated Financial Statements.

(I) Compliance declaration

The Consolidated Financial Statements are prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers (hereinafter referred to as the "Regulations") and IAS 34 "Interim Financial Reporting" endorsed and issued into effect by the FSC. The Consolidated Financial Statements do not include all the necessary information that should be disclosed in the full annual Consolidated Financial Statements prepared in accordance with the International Financial Reporting Standards, International Accounting Standards, Interpretations, and Interpretation Announcements (hereinafter referred to as the "FSC-endorsed International Financial Reporting and Accounting Standards") approved and issued by the FSC and in effect.

Except as described below, the significant accounting policies adopted in the Consolidated Financial Statements are the same as those in the Consolidated Financial Statements for the year 2023. For further details, please see Note 4 of the Consolidated Financial Statements for the year 2023.

- (II) Basis of consolidation
 - 1. Subsidiaries included in the consolidated financial statements

Subsidiaries included in the Consolidated Financial Statements:

Name of			Percenta	age of Share	holding	
Investor	Name of Subsidiary	Nature of Business	2024.6.30	2023.12.31	2023.6.30	Description
The Company	Succeed Agents Limited (B.V.I.) (referred to as "SA	Financial holding and investment	100.00%	100.00%	100.00%	Note 1
The Company	company") Renalysis Medical Care Co., Ltd.	Medical management consulting services	100.00%	100.00%	100.00%	

Name of			Percenta	ige of Share	holding	
Investor	Name of Subsidiary	Nature of Business	2024.6.30	2023.12.31	2023.6.30	Description
The Company	XinFu Healthcare Corp.	Medical management consulting services	100.00%	100.00%	100.00%	Note 1
The Company	Sin Hwa Co., Ltd.	Medical equipment trade	100.00%	100.00%	100.00%	Note 1
The Company	Sin Hwa Investment Co., Ltd.	Financial holding and investment	100.00%	100.00%	100.00%	Note 1
The Company	HC Healthcare Co., Ltd.	Medical management consulting services	100.00%	100.00%	100.00%	Note 1
SA company	PT Hiclearance Medical Indonesia (referred to as "HMI company")	Medical equipment trade	100.00%	100.00%	100.00%	Note 1
SA company	Moral Well Co., Ltd. (referred to as "MW company")	Financial holding and investment	100.00%	100.00%	100.00%	Note 1
MW company	Taicha Medical Corp. (Shanghai)	International trade and re-export trade	100.00%	100.00%	100.00%	Note 1

Note 1: Subsidiaries of little importance and the financial statements have not been audited by the CPA.

- 2. Subsidiaries not included in the Consolidated Financial Statements: None.
- (III) Standards for categorization of assets and liabilities classified as current and non-current

Assets that meet one of the following criteria are classified as current assets, and all other assets that are not current assets are classified as non-current assets of the Consolidated Companies.

- 1. The asset is expected to be realized in the normal operating cycle, or is intended to be sold or consumed;
- 2. The asset is held primarily for trading purposes;
- 3. The asset is realized within twelve months of the reporting period; or
- 4. The asset is cash or cash equivalents (as defined in IAS 7) unless there are restrictions on the exchange or settlement of the asset at least twelve months after the reporting period.

Liabilities that meet one of the following criteria are classified as current liabilities, and all other liabilities that are not current liabilities are classified as non-current liabilities of the Consolidated Companies.

- 1. The liability is expected to be settled in the normal operating cycle;
- 2. The liability is held primarily for trading purposes;
- 3. The liability is expected to be settled within twelve months of the reporting period; or
- 4. During the reporting period, there is no obligation to postpone the repayment of the debt for a minimum of twelve months following the end of the reporting period.

(IV) Income tax

The Consolidated Companies comply with IAS 34, "Interim Financial Reporting," paragraph B12. This standard specifies the measurement and disclosure of income tax expenses for the interim period.

The income tax expense is calculated by multiplying the net profit before tax for the reporting period by the management's best estimate of the effective tax rate for the full year. The current income tax expense and deferred income tax expense are then allocated based on the proportion of the estimated full-year current income tax expense and deferred income tax expense.

Income tax expenses that are recognized in equity items or other comprehensive income items are measured based on the temporary differences between the carrying amounts of the related assets and liabilities for financial reporting purposes and their tax bases. This measurement is done using the applicable tax rates that are expected to be realized or settled upon.

(V) Employee benefits

During the midterm period, the defined benefit plans are based on the actuarial retirement cost rate as of the reporting date of the previous year. The calculation covers the period from the beginning of the year to the end of the current period, and adjustments are made for significant market fluctuations, substantial reductions, liquidations, or other significant one-time events that occur after the reporting date.

V. Primary Sources of Uncertainties in Material Accounting Judgments, Estimates, and Assumptions

When preparing the Consolidated Financial Statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and the IAS 34 "Interim Financial Reporting" approved by the FSC, management is required to exercise judgment, make estimates, and make assumptions affecting the reported amounts of accounting policies, assets, liabilities, income, and expenses. Actual results may differ from the estimates.

When preparing the Consolidated Financial Statements, management made significant judgments and estimates regarding uncertainties in adopting the accounting policies of the Consolidated Companies, in accordance with Note 5 of the Consolidated Financial Statements for the year 2023.

VI. Details of Significant Accounts

Except as described below, there are no significant differences in the descriptions of the major accounting items in this Consolidated Financial Statement compared to the report in 2023. For related information, please refer to Note 6 of the 2023 Consolidated Financial Statement.

(I) Cash and cash equivalents

	_	2024.6.30	2023.12.31	2023.6.30
Cash on hand	\$	427	481	455
Demand deposits		365,514	311,156	374,859
Time deposits		61,200	89,500	94,008
Cash and cash equivalents in th consolidated statement of	ne			
cash flows	\$	427,141	401,137	469,322

(II) Financial assets and liabilities at fair value through profit or loss

1. Details are as follows:

	2024.6.30	2023.12.31	2023.6.30
Financial assets			
mandatorily measured at			
fair value through profit			
or loss:			
Beneficiary certificate - §	53,167	51,966	51,420
fund	,		
	2024.6.30	2023.12.31	2023.6.30
Financial liabilities held for			
trading:			
Forward foreign			
exchange contracts <u></u>	-	240	

2. Non-hedging derivative instruments

Derivative financial instrument transactions are undertaken to mitigate the exchange rate risk associated with business activities. The following is a detailed list of derivative instruments classified as financial assets measured at fair value through profit or loss and financial liabilities held for trading, which were not accounted for as hedging instruments by the Consolidated Companies:

	2023.12.31					
	Contract Amount	Currency	Maturity Period			
Derivative financial liabilities:						
Forward foreign exchange contracts	USD610	NTD to USD	2024.01.08~2024.02.15			

(III) Financial assets at fair value through other comprehensive income

	2024.6.30	2023.12.31	2023.6.30
Domestic unlisted			
(over-the-counter) stocks -			
Taiwan Depository &			
Clearing Corporation	\$ 268	268	268
Domestic unlisted			
(over-the-counter) stocks -			
EPED Inc.	 45,000	-	-
Total	\$ 45,268	268	268

1. The Consolidated Companies hold these investments in equity instruments as long-term strategic investments and not for trading purposes, therefore, they have been designated to be at fair value through other comprehensive income.

- 2. From January 1 to June 30, 2024, and 2023, the Consolidated Companies did not dispose of any strategic investments, and there were no transfers of accumulated gains and losses within the equity during that period.
- 3. The above financial assets have not been pledged as collateral.
- (IV) Accounts receivable, notes receivable, receivable financing lease payments, and collections

		2024.6.30	2023.12.31	2023.6.30
Notes receivable	\$	195,920	233,218	179,671
Long-term notes receivable		7,938	7,242	5,969
Accounts receivable		1,061,330	938,874	928,244
Receivables from related parties		71,570	85,080	104,282
Finance lease receivables		38,832	39,734	41,698
Long-term finance lease receivables		94,426	97,057	96,937
Overdue receivables		4,217	4,217	4,217
Deduction: Loss allowance		(27,742)	(28,151)	(24,889)
Net amount	<u>\$</u>	1,446,491	1,377,271	1,336,129

For details regarding the Consolidated Companies' bills for collection deposited in banks in the amounts of NT\$187,438 thousand, NT\$220,652 thousand, and NT\$169,329 thousand, respectively, as collateral for 10-20% of the forward letters of credit as of June 30, 2024, December 31, 2023, and June 30, 2023, please refer to Note 8.

Lease benefit maturity analysis for undiscounted lease benefits received after the reporting date:

		2024.6.30	2023.12.31	2023.6.30
Under 1 year	\$	43,809	44,710	47,105
1-2 year(s)		29,363	28,383	31,971
2-3 years		21,902	19,196	17,759
3-4 years		15,245	12,414	12,045
4-5 years		8,780	9,598	8,598
Over 5 years		31,693	40,699	39,858
Total lease investment		150,792	155,000	157,336
Unearned financing income		(17,534)	(18,209)	(18,701)
Present value of lease payments receivable		133,258	136,791	138,635
Deduction: Loss allowance		(1,333)	(1,368)	(1,386)
Net amount	<u>\$</u>	131,925	135,423	137,249
		2024.6.30	2023.12.31	2023.6.30
Overdue receivables	\$	4,217	4,217	4,217
Deduction: Loss allowance		(4,217)	(4,217)	(4,217)
	\$	-	-	-

The Consolidated Companies estimate expected credit losses for all receivables, accounts receivable, finance lease receivables, and collection items using a simplified approach. This approach involves measuring the expected credit losses over the lifetime of the assets. For this measurement purpose, these receivables are grouped based on shared credit risk characteristics representing the customer's ability to pay all amounts due according to the contractual terms, with forward-looking information accounted for as well. Expected credit loss analysis for the consolidated accounts receivable, notes receivable, finance leases receivable, and collections:

		2024.6.30	
	Carrying Amounts of Notes and Accounts Receivable, Finance Leases Receivable and Collections	Weighted Average Expected Credit Loss Rate	Allowance for Expected Credit Losses During the Period
Not overdue	\$ 1,412,372	0.07%	921
1-180 days overdue	33,579	10.19%	3,423
181-365 days overdue	9,474	48.45%	4,590
Over 366 days overdue	18,808	100%	18,808
	<u>\$ 1,474,233</u>		27,742
	,	2023.12.31	
	Carrying Amounts		
	of Notes and	Weighted	Allowance for
	Accounts	Average	Expected
	Receivable , Finance	Expected	Credit Losses
	Leases Receivable	Credit Loss	During the
	and Collections	Rate	Period
Not overdue	\$ 1,345,537	0.00%	-
1-180 days overdue	36,533	13.68%	4,998
181-365 days overdue	6,444	96.91%	6,245
Over 366 days overdue	16,908	100%	16,908
	<u>\$ 1,405,422</u>		28,151
		2023.6.30	
	Carrying Amounts		
	of Notes and	Weighted	Allowance for
	Accounts	Average	Expected
	Receivable, Finance	Expected	Credit Losses
	Leases Receivable	Credit Loss	During the
Not avandua	and Collections \$ 1,309,657	Rate	Period
Not overdue 1-180 days overdue	, , , ,	0.11%	1,387
181-365 days overdue	32,277 6,859	14.53% 96.02%	4,691 6,586
Over 366 days overdue	12,225	96.02% 100%	12,225
Over 500 days overdue		100/0	24,889
	<u>\$ 1,361,018</u>		24,009

Changes in loss allowance for notes and accounts receivable, finance lease receivable and collections of the Consolidated Companies:

		Jan	uary to June 2024	January to June 2023	
Beginning balance		\$	28,151	19,499	
Recognized impairment	loss (reversal)	(431)	5,367	
Foreign currency exchan	nge gain/loss	- 	22	23	
Ending balance		<u>\$</u>	27,742	24,889	
Inventories					
	2	024.6.30	2023.12.31	2023.6.30	
Commodities	\$	621,983	609,713	586,494	
Goods in transit		-	35,744	-	
	\$	621.983	645.457	586,494	

For the periods from January 1 to June 30, 2024, April 1 to June 30, 2023, and January 1 to June 30, 2023, improvements in previously identified factors causing the net realizable value of inventory to be lower than cost have resulted in an increase in net realizable value. This has led to a reduction in cost of goods sold by NT\$983 thousand, NT\$13,710 thousand, and NT\$8,506 thousand, respectively.

From April 1 to June 30, 2024, inventory was adjusted to its net realizable value, leading to an inventory impairment loss of NT\$1,008 thousand, and reported as operating costs.

As of June 30, 2024, December 31, 2023, and June 30, 2023, none of the inventories of the Consolidated Companies have been pledged as collaterals.

(VI) Investments accounted for using the equity method

(V)

1. Investments of the Consolidated Companies accounted for under the equity method at the reporting date:

	 2024.6.30	2023.12.31	2023.6.30	
Associate	\$ 120,340	116,390	112,430	

The financial information of associates of the Consolidated Companies, which are individually immaterial, and accounted for using the equity method, and is included in the Consolidated Financial Statements as follows:

	202	24.6.30	2023.12.31	2023.6.30
Closing aggregated				
carrying amount of				
interests in individually				
insignificant related				
parties	<u>\$</u>	120,340	116,39	0 112,430

	-	l to June 2024	April to June 2023	January to June 2024	January to June 2023
Equity owned by the Consolidated Companies Net profit from ongoing operations for the current period	: \$	3,877	1,348	8,224	5,997
Other comprehensive income Total comprehensive income	<u>\$</u>	- 3,877	-	8,224	

2. As of June 30, 2024, December 31, 2023, and June 30, 2023, no investments in related parties of the Consolidated Companies, accounted for under the equity method, have been pledged as collaterals.

3. Investments accounted for using the equity method without auditing

Investee and Consolidated Companies that use the equity method calculate their share of profit and other comprehensive income based on unaudited financial statements.

(VII) Property, plant, and equipment

Changes in cost and depreciation of properties, plants, and equipment of the Consolidated Companies from January 1 to June 30, 2024, and 2023:

		Land	Building and Construction	Transportation Equipment	Office Equipment	Leased Assets	Construction in Process	Total
Cost:					<u> </u>			
Balance as of								
January 1,								
2024	\$	412,632	455,875	4,565	83,044	417,090	-	1,373,206
Addition		-	1,133	110	5,041	20,170	-	26,454
Reclassifications		-	-	-	8,012	43,037	-	51,049
Disposal and								
obsolescence		-	-	-	(1,777)	(3,253)	-	(5,030)
Effects of								
exchange rate								
changes		-		-	7	326	-	333
Balance as of								
June 30, 2024	<u>\$</u>	412,632	457,008	4,675	94,327	477,370	-	1,446,012
Balance as of								
January 1,			10 (000	1.0==		100 (01	1 - 000	
2023	\$	412,632	426,833	1,877	64,701	423,601	17,003	1,346,647
Addition		-	158	2,567	3,633	3,145	7,870	17,373
Reclassifications		-	-	-	3,694	25,370	-	29,064
Disposal and					((50)	(2,505)		(2.25.4)
obsolescence		-	-	-	(659)	(2,595)	-	(3,254)
Effects of								
exchange rate					1	371		272
changes Balance as of		-		-	I	3/1	-	372
June 30, 2023	\$	412.632	426.991	4.444	71,370	449,892	24,873	1.390.202
Depreciation:	<u></u>	712,032	420,771		/1,5/0	447,072	24,075	1,070,202
Balance as of								
January 1,								
2024	\$	-	67,549	1,984	35,864	206,259	-	311,656
_ • _ ·	4		, <i></i>	-,,, 0 .	,	,,		2 ,

	Land	Building and Construction	Transportation Equipment	Office Equipment	Leased Assets	Construction in Process	Total
Current year	 						·
depreciation	-	5,567	261	7,073	28,228	-	41,129
Reclassifications	-	-	-	-	(31)	-	(31)
Disposal and							
obsolescence	-	-	-	(981)	(2,577)	-	(3,558)
Effects of							
exchange rate							
changes	 -	-	-	2	48	-	50
Balance as of							
June 30, 2024	\$ -	73,116	2,245	41,958	231,927	-	349,246
Balance as of							
January 1,							
2023	\$ -	57,716	1,563	26,132	210,671	-	296,082
Current year							
depreciation	-	4,657	162	5,417	28,613	-	38,849
Reclassifications	-	-	-	-	(300)	-	(300)
Disposal and							
obsolescence	-	-	-	(659)	(2,326)	-	(2,985)
Effects of							
exchange rate							
changes	 -				23		23
Balance as of							
June 30, 2023	\$ -	62,373	1,725	30,890	236,681	-	331,669
Carrying amount:							
January 1, 2024	\$ 412,632	388,326	2,581	47,180	210,831		1,061,550
June 30, 2024	\$ 412,632	383,892	2,430	52,369	245,443		1,096,766
January 1, 2023	\$ 412,632	369,117	314	38,569	212,930	17,003	1,050,565
June 30, 2023	\$ 412,632	364,618	2,719	40,480	213,211	24,873	1,058,533

For details regarding the Consolidated Companies' property, plant and equipment pledged as collaterals for loans and lines of credit, please refer to Note 8.

(VIII) Right-of-use assets

Changes in cost and depreciation of leased premises, buildings, and transportation equipment of the Consolidated Companies:

	Building and Construction	Transportation Equipment	Total
Costs of right-of-use assets:			
Balance as of January 1, 2024 \$	5 781,067	1,309	782,376
Addition	111,403	-	111,403
Decrease	(37,572)	-	(37,572)
Balance as of June 30, 2024	<u> </u>	1,309	856,207
Balance as of January 1, 2023 S	5 757,462	-	757,462
Addition	16,486	1,309	17,795
Decrease	(21,061)	-	(21,061)
Balance as of June 30, 2023	5 752,887	1,309	754,196
Accumulated depreciation of right-of-use assets:			
Balance as of January 1, 2024 S	§ 262,521	400	262,921
Current period depreciation	38,266	218	38,484

(IX)

January 1, 2023

June 30, 2023

		ding and struction	Transportation Equipment	Total
Decrease		(24,248)	-	(24,248)
Balance as of June 30, 2024	\$	276,539	618	277,157
Balance as of January 1, 2023	\$	250,713	-	250,713
Current period depreciation		35,968	182	36,150
Decrease		(20,824)	-	(20,824)
Balance as of June 30, 2023	\$	265,857	182	266,039
Carrying amount: January 1, 2024	\$	518,546	909	519,455
June 30, 2024	\$	578,359	691	579,050
January 1, 2023	<u>\$</u>	506,749		506,749
June 30, 2023	<u>\$</u>	487,030	1,127	488,157
Investment properties				
	La	nd and	Building and	
	Impr	ovements	Construction	Total
Carrying amount:				
January 1, 2024	\$	25,736	365	26,101
June 30, 2024	\$	25,736	360	26,096

There were no significant additions, disposals, impairments, or reversals of investment properties of the Consolidated Companies during the period from January 1 to June 30, 2024 and 2023. Please refer to Note 12 (I) for the depreciation amount for this period. For other related information, please see Note 6 (IX) of the 2023 Consolidated Financial Statements.

\$

\$

25.736

25,736

374

370

26,110

26,106

As of June 30, 2024, December 31, 2023, and June 30, 2023, no investment properties of the Consolidated Companies were pledged as collaterals.

There are no significant differences in the disclosed information regarding the fair value of investment properties between the Consolidated Financial Statements of the Consolidated Companies and Note 6 (IX) to the 2023 Consolidated Financial Statements.

(X) Intangible assets

Changes in cost and amortization of intangible assets of the Consolidated Companies from January 1 to June 30, 2024 and 2023:

			Other Intangible	
	G	oodwill	Assets	Total
Cost:				
Balance as of January 1, 2024 (opening balance)	<u>\$</u>	116,961	119,910	236,871
Balance as of January 1, 2023	\$	116,961	96,100	213,061
Addition		-	2,381	2,381
Reclassifications		-	21,429	21,429
Balance as of June 30, 2023	<u>\$</u>	116,961	119,910	236,871
Amortization:				
Balance as of January 1, 2024	\$	-	47,892	47,892
Current period amortization		-	8,280	8,280
Balance as of June 30, 2024	<u>\$</u>	-	56,172	56,172
Balance as of January 1, 2023	\$	-	34,309	34,309
Current period amortization		-	6,792	6,792
Balance as of June 30, 2023	<u>\$</u>		41,101	41,101
Carrying amount:				
January 1, 2024	<u>\$</u>	116,961	72,018	<u>188,979</u>
June 30, 2024	\$	116,961	63,738	180,699
January 1, 2023	\$	116,961	61,791	178,752
June 30, 2023	<u>\$</u>	116,961	78,809	195,770

As of June 30, 2024, December 31, 2023, and June 30, 2023, the Consolidated Companies' intangible assets have not been used as collateral or security.

(XI) Short-term loans

Short-term loans of the Consolidated Companies:

		2024.6.30	2023.12.31	2023.6.30
Unsecured bank loans	\$	220,000	-	-
Secured bank loans		97,987	91,565	81,565
Total	<u>\$</u>	317,987	91,565	81,565
Unused credit line	<u>\$</u>	905,176	1,050,212	<u>1,151,857</u>
Interest rate	<u> </u>	<u>82%~2.00%</u>	1.75%	<u>1.50%~1.75%</u>

Assets of the Consolidated Companies pledged as collaterals for bank loans are described in Note 8.

(XII) Long-term loans

Long-term loans of the Consolidated Companies:

		2024.6.30	2023.12.31	2023.6.30
Borrowing from non-financial institutions	\$	-	12,357	13,119
Deduction: Portion due within		-	-	-
one year				
Total	\$	-	12,357	13,119
Unused credit line	<u>\$</u>			
Interest rate		_	3%	3%

As of December 31, 2023, and June 30, 2023, no long-term loans unsecured by assets of the Consolidated Companies were pledged as collaterals.

(XIII) Lease liabilities

Carrying amount of the consolidated lease liabilities:

	20)24.6.30	2023.12.31	2023.6.30
Current	<u>\$</u>	77,290	71,364	66,349
Non-current	<u>\$</u>	525,112	469,455	442,587

For an analysis of maturity, please refer to Note 6 (XXIII): Financial Instruments.

Leases recognized in the income statement:

	Apr	il to June 2024	April to June 2023	January to June 2024	January to June 2023
Interest expenses					
for lease					
liabilities	<u>\$</u>	1,921	1,565	3,654	3,165
Changes in lease					
payments not					
accounted for in					
measurement of					
lease liabilities	\$	1,323	746	2,088	<u> 1,691</u>
Income from					
subleasing					
right-of-use					
assets	\$	22,447	20,706	43,998	41,084
Short-term lease					
expenses	\$	354	224	717	314
Expenses for					
low-value lease					
assets (excluding	g				
low-value					
short-term					
leases)	\$	51	777	85	1,236
leases)	<u>)</u>	51		85	1,23

Leases recognized in the cash flow statement:

		nuary to ine 2024	January to June 2023
Total cash flows on lease	<u>\$</u>	42,591	41,618

1. Real estate, construction, and transportation equipment leasing

The Consolidated Companies lease buildings and structures as office spaces and storage locations, and the usual lease term is 3-10 years for office spaces, 2 years for storage locations. Some leases offer the option to extend for the same duration as the original contract when the lease term expires. The lease term for transportation equipment is three years.

For right-of-use assets subleased under operating leases, please refer to Note 6 (XIV).

Certain lease agreements offer extension options, but specific terms and conditions agreed upon may differ within the Consolidated Companies as these agreements are handled independently by various regions. These options are enforceable only by the Consolidated Companies and not by the lessor. Where it is not reasonably certain that the optional extended lease term will be exercised, the lease liability does not include payments for the period covered by the option.

2. Other leases

The Consolidated Companies lease office equipment and other assets for a period of one to two years under short-term or low-value leases. In accordance with the exemption recognition rules, the Consolidated Companies do not recognize the associated right-of-use assets and lease liabilities.

(XIV) Operating leases

The Consolidated Companies had no significant new operating lease agreements from January 1 to June 30, 2024 and 2023. For related information, please refer to Note 6 (XV) of the 2023 Consolidated Financial Statements.

- (XV) Employee benefits
 - 1. Defined benefit plans

The details of expenses reported by the Consolidated Companies are as follows:

	April to June 2024	April to June 2023	January to June 2024	January to June 2023
Operating costs $\overline{\$}$ Operating	5	5	11	11
expenses	1,427	1,426	2,857	2,856
Total <u>S</u>	1,432	1,431	2,868	2,867

2. Defined contribution plans

Pension costs under the defined contribution plan amounted are as follows, and have been allocated to the Bureau of Labor Insurance:

	April to June 2024	April to June 2023	January to June 2024	January to June 2023
Operating costs $\overline{\$}$ Operating	729	728	1,456	1,457
expenses	3,206	3,007	6,248	5,899
Total <u>§</u>	3,935	3,735	7,704	7,356

- (XVI) Income tax
 - 1. Detailed breakdown of the Consolidated Companies' income tax expenses:

	Apr	il to June 2024	April to June 2023	January to June 2024	January to June 2023
Income tax expenses	<u>\$</u>	26,111	10,89	95 48,708	32,198

- 2. The Consolidated Companies have no income tax expense that is recognized directly in equity and other comprehensive income.
- 3. Income tax assessment

The income tax settlement declarations of the Company, Renalysis Medical Care, XinFu Healthcare, Sin Hwa, Sin Hwa Investment, and HC-Healthcare have been approved by tax authorities until 2021.

(XVII) Capital and other equity

Except as described below, there were no significant changes in capital and other equity for the Consolidated Companies from January 1 to June 30, 2024 and 2023. For related information, please refer to Note 6 (XVIII) of the 2023 Consolidated Financial Statements.

1. Issuance of common shares

On October 20, 2022, the Board of Directors passed a resolution to increase cash capital by issue 4,000 thousand new shares of common stock at a premium of NT\$125 per share, resulting in a total amount of NT\$498,750 thousand (excluding issuance costs of NT\$1,250 thousand). The reference date is April 7, 2023; all payments for the issue shares have been received, and relevant legal registration procedures were completed on April 25, 2023.

2. Capital surplus

Breakdown of the Company's capital surplus is as follows:

	2024.6.30	2023.12.31	2023.6.30
Premium on share issuance $\$$	1,591,611	1,591,611	1,591,611
Employees stock option	9,174	9,174	9,174
Expired stock options	706	706	706
Income from donations	497	497	469
<u>\$</u>	1,601,988	1,601,988	1,601,960

3. Retained earnings

In accordance with the Articles of Incorporation, if the annual final accounts show a surplus, taxes should be paid first to offset any past losses, then 10% of the surplus should be allocated to legal reserve, unless the legal reserve has already reached the paid-in capital. Furthermore, a special reserve may be set aside based on operational needs and legal requirements of the Consolidated Companies. Afterwards, if there is still a surplus and unappropriated earnings from the beginning of the period, the Board of Directors shall propose a earnings distribution plan and submit for approval at the shareholders' meeting.

The Company is currently experiencing a period of business growth, and its dividend policy prioritizes the Company's future development and financial condition, while also ensuring reasonable remuneration for shareholders. As a result, at least fifty percent of the dividends and profits distributed to shareholders are in the form of cash dividends.

(1) Distribution of earnings

At the shareholders' meetings held on May 29, 2024 and June 14, 2023, the Company resolved to distribute dividends for 2023 and 2022, respectively. Dividends distributed to shareholders are detailed as follows:

		2023			22	
				Allotment		
	Allo	tment		Ratio		
	Ratio	(NT\$)	Amount	(NT\$)	Amount	
Cash dividends	\$	7.00_	311,647	7.00_	311,647	

(XVIII) Share-based payment

On October 20, 2022, the Board of Directors resolved to increase the Consolidated Companies' cash capital, of which 600 thousand shares were reserved for employee subscription. Relevant information is as follows:

	Cash Capital Increase with Reserved Employee Subscription Rights
Date given	2023.2.15
Quantity given	600 thousand shares
Executed quantity	600 thousand shares
Vesting period	Immediate vesting

The Consolidated Companies has assigned a fair value of NT\$20.574 per unit for retained cash capital increase and employee stock options. For the period from January 1 to June 30, 2023, compensation cost amounted to NT\$12,344 thousand and was recognized as labor expenses and classified under operating expenses.

(XIX) Earnings per share

The calculation of basic earnings per share is as follows:

	Ар	ril to June 2024	April to June 2023	January to June 2024	January to June 2023
Basic earnings per share					
Net income attributable to					
the Company for the					
current period	\$	109,039	92,228	205,142	177,526
Net profit attributable to					
the common equity					
holders of the Company	\$	109,039	92,228	205,142	177,526
Weighted average number					
of common shares					
outstanding (thousand					
shares)		44,521	44,257	44,521	42,399
	\$	2.45	2.08	4.61	4.19

	Ap	ril to June 2024	April to June 2023	January to June 2024	January to June 2023
Diluted earnings per share		_			
Net income attributable					
to the Company for	<i>•</i>	100.000			
the current period	\$	109,039	92,228	205,142	177,526
Effect of potentially					
dilutive common shares:					
Net profit attributable		-	-	-	
to the common					
equity holders of the					
Company (After					
adjusting for the					
effects of dilutive					
potential common					
shares)	\$	109,039	92,228	205,142	177,526
Weighted average					
number of common					
shares outstanding					
(thousand shares)		44,521	44,257	44,521	42,399
Effect of potentially					
dilutive common					
shares: Effect of employee					
stock compensation					
(thousand shares)		18	14	27	25
Impact of stock option		10	17	27	23
issuance (thousand					
shares)		_	40	_	169
Weighted average					
number of common					
shares outstanding					
(After adjusting for					
the effects of dilutive	;				
potential common					
shares) (thousand		44.539	44.311	44,548	42,593
shares)				,	,,,,,,
	\$	2.45	2.08	4.60	4.17

⁽XX) Revenue from contracts with customers

1. Revenue breakdown

	April to June 2024			
	Η	Iemodialysis	Other	
		Division	Divisions	Total
Main markets in the region	n:			
Taiwan	\$	699,133	388,651	1,087,784
China		-	1,907	1,907
Indonesia		7,295	-	7,295
	<u>\$</u>	706,428	390,558	1,096,986
Main products/services: Dialyzer and blood tubing	\$	328,120	-	328,120

		iodialysis ivision	Other Divisions	Total
Erythropoietin and liquid medications		299,067	-	299,067
Hemodialysis machine, maintenance and repair		45,982	-	45,982
Anesthesia and sleep		-	93,961	93,961
Lease income		1,516	49,404	50,920
Service revenue		2,948	30,943	33,891
Others		28,795	216,250	245,045
	\$	706,428	390,558	1,096,986
		Ар		
	Hen	nodialysis	Other	
	D	ivision	Divisions	Total
Main markets in the region:				
Taiwan	\$	704,813	247,763	952,576
China		-	2,162	2,162
Indonesia		1,462	-	1,462
	<u>\$</u>	706,275	249,925	956,200
Main products/services: Dialyzer and blood				
tubing	\$	320,810	-	320,810
Erythropoietin and liquid				
medications		289,753	-	289,753
Hemodialysis machine, maintenance and				
repair		62,201	-	62,201
Anesthesia and sleep		-	51,632	51,632
Lease income		1,180	48,524	49,704
Service revenue		3,062	31,447	34,509
Others		29,269	118,322	147,591
	<u>\$</u>	706,275	249,925	956,200

	January to June 2024			
	Η	emodialysis Division	Other Divisions	Total
Main markets in the region: Taiwan	\$	1,412,659	635,348	2,048,007
China	Φ	-	2,813	2,048,007
Indonesia		11,009	-	11,009
	\$	1,423,668	638,161	2,061,829

	January to June 2024			
-	Hemodialysis Division	Other Divisions	Total	
Main products/services:				
Dialyzer and blood				
tubing	677,628	-	677,628	
Erythropoietin and liquid				
medications	596,486	-	596,486	
Hemodialysis machine,				
maintenance and repair	79,704	-	79,704	
Respiration and				
anesthesia	-	153,997	153,997	
Lease income	3,262	97,462	100,724	
Service revenue	6,737	62,602	69,339	
Others	59,851	324,100	383,951	
	<u>5 1,423,668</u>	638,161	2,061,829	

		Janu	ary to June 2023	
	ł	Hemodialysis	Other	
		Division	Divisions	Total
Main markets in the region:				
Taiwan	\$	1,405,128	513,083	1,918,211
China		-	6,461	6,461
Indonesia		4,507	-	4,507
	\$	1,409,635	519,544	<u>1,929,179</u>
Main products/services:				
Dialyzer and blood				
tubing	\$	656,155	-	656,155
Erythropoietin and liquid				
medications		591,656	-	591,656
Hemodialysis machine,				
maintenance and repair	•	94,735	-	94,735
Anesthesia and sleep		-	117,799	117,799
Lease income		1,707	95,356	97,063
Service revenue		6,435	62,578	69,013
Others		58,947	243,811	302,758
	\$	1,409,635	519,544	1,929,179
Contract balance				
		2024.6.30	2023.12.31	2023.6.30
Notes receivable	\$	195,920	233,218	179,671
Long-term notes receivable		7,938	7,242	5,969
Accounts receivable		1,061,330	938,874	928,244
Receivables from related				
parties		71,570	85,080	104,282
Finance lease receivables		38,832	39,734	41,698

2.

	2024.6.30	2023.12.31	2023.6.30
Long-term finance lease			
receivables	94,426	97,057	96,937
Overdue receivables	4,217	4,217	4,217
Deduction: Loss allowance	(27,742)	(28,151)	(24,889)
Total	<u> </u>	1,377,271	1,336,129
	2024.6.30	2023.12.31	2023.6.30
Contractual liabilities for			
maintenance and repair			
services	<u> </u>	32,633	29,025

Please refer to Note 6 (IV) for the disclosure of notes receivable, accounts receivable and finance lease receivables and their impairment.

Revenue recognized from January 1 to June 30, 2024, and 2023 for the initial balance of contract liabilities as of January 1, 2024, and 2023, was NT\$5,725 thousand and NT\$5,647 thousand, respectively.

Changes in contract liabilities are mainly due to timing difference between the Consolidated Companies' performance obligations and customer payment.

3. Allocation to transaction price of outstanding performance obligations

On June 30, 2024, December 31, 2023, and June 30, 2023, the total transaction price for the extended warranty service allocated to outstanding performance obligations, which has not yet been fulfilled, was NT\$42,116 thousand, NT\$32,633 thousand, and NT\$29,025 thousand, respectively. The Consolidated Companies shall recognize this revenue gradually as the service is provided, which is expected to be completed within two to six years.

(XXI) Remuneration for employees, directors, and supervisors

According to the Articles of Incorporation of the Company, if there are profits for the year, the allocation for the remuneration of employees shall be at least 1%, and that of directors and supervisors shall be no more than 3%. However, the Consolidated Companies should reserve a deficit compensation amount in advance losses have accumulated. Remuneration in stock or cash is targeted at employees of the Consolidated Companies who meet certain criteria.

The estimated remuneration for employees, directors, and supervisors of the Company is as follows:

	April to June 202	April to June 4 2023	January to June 2024	January to June 2023
Remuneration for				
employees Remuneration for directors and	\$ 1,33	9 1,050	2,513	2,083
supervisors	4,01	9 3,151	7,541	6,249
	<u>\$ 5,35</u>	58 4,201	10,054	8,332

Remuneration to employees, directors, and supervisors was estimated by multiplying the net profit before tax for each respective period by the percentage of employee remuneration and director and supervisor remuneration specified in the Company's Articles of Incorporation. The remuneration was recorded as operating expenses for the respective period and was all paid in cash. Any differences between the actual amount distributed in the following year and the estimated amount are treated as changes in accounting estimate, and are recognized in the profit or loss of the subsequent year. For related information, please refer to the Market Observation Post System (MOPS).

The employee remuneration provisions for the fiscal years 2023 and 2022 of the Company amounted to NT\$4,320 thousand and NT\$4,488 thousand, respectively. The remuneration provision for directors and supervisors amounted to NT\$12,959 thousand and NT\$13,463 thousand, respectively. These amounts are consistent with the actual payments made. For more information, please refer to the MOPS.

- (XXII) Non-operating income and expenses
 - 1. Interest income

Interest income of the Consolidated Companies:

	-	il to June 2024	April to June 2023	January to June 2024	January to June 2023
Interest on bank deposits Interest income on	\$	1,314	1,788	1,843	2,089
finance lease receivables Other interest		1,599	2,020	3,122	3,936
income		12	4	43	22
	\$	2,925	3,812	5,008	6,047

2. Other income

Other income of the Consolidated Companies:

		April to June	January to June	January to June 2023	
	April to June 2024	2023	2024		
Other income	<u>\$ 4,999</u>	2,071	10,551	3,636	

3. Other gains and losses

Other gains and losses of the Consolidated Companies:

	April to June 2024		April to June 2023	January to June 2024	January to June 2023	
Gains on foreign currency						
exchange	\$	5,473	4,381	6,965	7,121	
Gains on disposal of propert	ty,					
plant, and equipment		542	169	1,094	460	
Net gain on financial assets	at					
fair value through profit of	or					
loss		727	484	2,343	290	
Others		(739)	(324)	(740)	(610)	
	\$	6,003	4,710	9,662	7,261	

4. Finance costs

Finance costs of the Consolidated Companies:

	April to Ju	une 2024	April to June 2023	January to June 2024	January to June 2023
Interest expenses	\$	2,853	3,558	5,360	7,448

(XXIII) Financial instruments

Apart from the exceptions mentioned below, there have been no significant changes in the fair value of the financial instruments of the Consolidated Companies, nor in its exposure to credit risk, liquidity risk, and market risk. For further details, please consult Note 6 (XXIV) of the 2023 Consolidated Financial Statements.

1. Liquidity risk

The table below displays maturity dates of financial liabilities, including interest but excluding the impact of netting agreements.

	Carr Amo		Contract Cash Flow	Within 1 Year	1-5 Years	Over 5 Years
June 30, 2024		unt	Cush Flow	1 cui	1010015	I curs
Non-derivative financial liabilities						
	\$	317,987	318,386	318,386	-	-
Notes payable		7,651	7,651	7,651	-	-
Accounts payable	(500,331	600,331	600,331	-	-
Payables to related parties		2,293	2,293	2,293	-	-
Other payables		154,667	154,667	154,667	-	-
Other payables to related parties		9,353	9,353	9,353	-	-
Dividends payable		311,647	311,647	311,647	-	-
Lease liabilities		502,402	645,807	84,837	284,744	276,226
		006,331	2.050.135	1.489.165	284,744	276,226
December 31, 2023	,		, ,	, ,	,	
Non-derivative financial liabilities						
	\$	91,565	91,712	91,712	-	-
Notes payable	*	7,521	7,521	7,521	-	-
Accounts payable	(581,169	681,169	681,169	-	-
Payables to related parties		2,282	2,282	2,282	-	-
Other payables		184,597	184,597	184,597	-	-
Other payables to related parties		14,665	14,665	14,665	-	-
Long-term loans		12,357	13,701	374	13,327	-
Lease liabilities	4	540,819	574,872	77,552	253,146	244,174
Other forward exchange		-)))) -	, .
contracts		240	240	240	-	-
	\$ 1.5	535.215	1,570,759	1.060.112	266,473	244,174
June 30, 2023	,			, ,	,	,
Non-derivative financial liabilities						
Short-term loans	\$	81,565	81,900	81,900	-	-
Notes payable	•	7,152	7,152	7,152	-	-
Accounts payable		549,843	549,843	549,843	-	-
Payables to related parties		1,873	1,873	1,873	-	-
Other payables		143,195	143,195	143,195	-	-
Other payables to related parties		7,082	7,082	7,082	-	-
Dividends payable		311,647	311,647	311,647	-	-
Long-term loans		13,119	14,033	368	13,665	-
Lease liabilities		508,936	542,123	72,086	230,688	239,349
	\$ 1,0	624,412	1,658,848	1,175,146	244,353	239,349

The Consolidated Companies does not anticipate cash flows for the maturity analysis to occur earlier or differ significantly in amount.

- 2. Foreign exchange risk
 - (1) Exposure to foreign exchange risk

Consolidated financial assets and liabilities that are exposed to significant foreign exchange rate risk:

	2024.6.30			2023.12.31			2023.6.30		
	Foreign	Exchange		Foreign	Exchange		Foreign	Exchange	
	Currency	Rate	NT\$	Currency	Rate	NT\$	Currency	Rate	NT\$
Financial assets									
Monetary items									
JPY	\$ 224,377	0.2015	45,212	34,345	0.2171	7,456	284,686	0.2150	61,207
USD	143	32.438	4,639	184	30.705	5,650	220	31.140	6,851
Financial liabilities	<u>.</u>								
Monetary items									
JPY	618,330	0.2015	124,593	489,429	0.2171	106,255	431,651	0.2150	92,805
USD	1,828	32.438	59,297	1,216	30.705	37,337	1,674	31.140	52,128

(2) Sensitivity analysis

The Consolidated Companies' exposure to foreign exchange risk on monetary items mainly arises from cash, cash equivalents, and accounts payable denominated in foreign currencies, which generate foreign exchange gains or losses upon translation. As of June 30, 2024, and 2023, if NT\$ depreciates or appreciates by 0.25% against US\$ and JPY, with all other factors remaining constant, the net income before tax for January 1 to June 30, 2024, and 2023, would decrease or increase by NT\$335 thousand and NT\$192 thousand, respectively.

(3) Exchange gains and losses on monetary items

The Consolidated Companies disclose foreign currency exchange gains and losses (including realized and unrealized) for monetary items on a consolidated basis. For the periods from April 1 to June 30, 2024 and 2023, and from January 1 to June 30, 2024 and 2023, the foreign currency exchange gains and losses were NT\$5,473 thousand, NT\$4,381 thousand, NT\$6,965 thousand, and NT\$7,121 thousand, respectively.

3. Interest rate analysis

Financial assets and financial liabilities with interest rate risk of the Consolidated Companies:

		2024.6.30	2023.12.31	2023.6.30
Variable rate instruments (b	oook			
value)				
Financial assets	\$	483,975	459,551	519,269
Financial liabilities		317,987	103,922	94,684

Financial assets and financial liabilities with interest rate risk of the Consolidated Companies are described in the liquidity risk management segment of these notes.

The sensitivity analysis below is prepared based on the risk exposure of non-derivative instruments to the interest rates at the report date. Floating rate assets are analyzed by assuming that the amount of assets outstanding at the reporting date is outstanding for the entire year.

If the interest rate increased or decreased by 0.25%, the Consolidated Companies' net income before tax from January 1 to June 30, 2024, and 2023, would have increased or decreased by NT\$207 thousand and NT\$531 thousand, respectively, with all other variables remaining constant, which was mainly due to the Consolidated Companies' changing bank deposit rates and loans.

- 4. Information on fair value
 - (1) Classification of financial instruments and determination of fair value

The Consolidated Companies measure financial assets and liabilities at fair value through profit or loss, and financial assets at fair value through other comprehensive income on a recurring basis. Carrying amounts and fair values of various financial assets and financial liabilities (including fair value hierarchy information, but excluding financial instruments measured at fair value where the carrying amount is a reasonable approximation of fair value, and lease liabilities, of which fair value information disclosure is not required):

				2024.6.30		
		_		Fair '	Value	
	Carry Amo	0	Level 1	Level 2	Level 3	Total
Financial assets at fair value through profit or loss:						
Beneficiary certificate - fund Financial assets at fair value through	\$ 5	53,167	53,167	-	-	53,167
other comprehensive income	2	45,268	-	-	45,268	45,268
Total	<u>\$</u>	98,435				
				2023.12.31		
				Fair '	Value	
	Carry Amo	-	Level 1	Level 2	Level 3	Total
Financial assets at fair value through profit or loss:						
Beneficiary certificate - fund Financial assets at fair value through	\$ 5	51,966	51,966	-	-	51,966
other comprehensive income		268	-	-	268	268
Total	<u>\$</u>	52,234				
				2023.6.30		
		-		Fair '	Value	
	Carry Amo	-	Level 1	Level 2	Level 3	Total
Financial assets at fair value through profit or loss:						
Beneficiary certificate - fund	\$ 5	51,420	51,420	-	-	51,420
Financial assets at fair value through		• • •			•	
other comprehensive income Total		268	-	-	268	268
10(a)	<u>\$</u>	51 <u>,688</u>				

- (2) Fair value measurement techniques for financial instruments at fair value
 - A. Non-derivative financial instruments

The fair value of financial instruments is determined based on active market quotations when they are available. The fair value of listed (OTC) equity instruments and debt instruments with active market quotations is determined based on the market prices of the Central Government Bonds for popular securities.

If a public quotation for the financial instrument can be obtained from an exchange, broker, underwriter, industry association, pricing service or competent authority in a timely and regular manner, and if the price reflects actual and frequent transactions by fair market traders, then the financial instrument is considered to have an active market with public quotations. If the above conditions are not met, the market shall be deemed inactive. Generally, substantial disparities or notable increases between buying and selling prices, and low trading volume, are all indications of an inactive market.

Classification and attributes of financial instruments with active markets of the Consolidated Companies:

Domestic funds and forward foreign exchange contracts and other financial assets and liabilities that are traded in active markets are valued at fair value, which is determined based on market quotations.

Apart from the financial instruments mentioned above that have active markets, the fair value of other financial instruments is determined using valuation techniques or by referring to quotes from counterparties. The fair value obtained through valuation techniques can be referenced to the current fair value of other financial instruments with substantially similar conditions and characteristics, discounted cash flow methods, or other valuation techniques, including models that use market information available on the reporting date (such as the Taipei Exchange reference yield curve, or Reuters commercial paper rate average quotes).

(3) Fluctuations in level 3

	Measured at Fair Value through Other Comprehensive Income		
January 1, 2024	\$	268	
Purchases		45,000	
June 30, 2024	<u>\$</u>	45,268	
June 30, 2023 (opening balance)	<u>\$</u>	268	

(4) Quantitative information on fair value measurement of significant unobservable inputs (Level 3)

The fair value measurement of the Consolidated Companies is classified as Level 3, primarily due to the fair value measurement of financial assets recognized in other comprehensive income - equity securities.

Investments in debt instrument without active market of the Consolidated Companies involve multiple significant unobservable input values. These values are independent of each other and therefore have no correlation.

The list of quantified information for significant unobservable input values is as follows:

Item	Evaluation		Significant Unobservable Input Values	Relationship between Significant Unobservable Input Values and Fair Value
Financial assets at fair value through other comprehensive income - Investments in debt instrument without active market	Comparable to the Company Act	•	The price-to-earnings• ratio multiple (as of June 30, 2024: 10.15%).	The fair value increases as the multiple and control premium increase The fair value decreases as the lack of
For the foir w	alua mansurama	nt	of Loval 3 a consist	market liquidity discount increases

(5) For the fair value measurement of Level 3, a sensitivity analysis is conducted to assess the impact of reasonably possible alternative assumptions on the fair value

The fair value measurement of financial instruments by the Consolidated Companies is reasonable. However, employing alternative valuation models or parameters may yield varying valuation outcomes. With regards to financial instruments classified as Level 3, the changes in valuation parameters have the following impact on the current period's profit or other comprehensive income:

			Reflecte	Changes Are d in Other nsive Income
	Input Value	Upward or Downward	Favorable Changes	Unfavorable Changes
June 30, 2024 Financial assets at fair value through other comprehensive income	10.15	1%	426	(426)

Favorable and unfavorable changes for the Consolidated Companies refer to fluctuations in fair value, which are calculated using valuation techniques based on varying degrees of unobservable inputs. If the fair value of financial instruments is influenced by multiple inputs, the table above only shows the impact of a single change in input value. It does not take into account the correlation and variability between input values.

(XXIV) Financial risk management

There have been no significant changes to the financial risk management objectives and policies of the Consolidated Companies, as stated in Note 6 (XXV) of 2023 Consolidated Financial Statements.

(XXV) Capital management

The capital management objectives, policies, and procedures of the Consolidated Companies remain consistent with those disclosed in the 2023 Consolidated Financial Statements. Furthermore, there have been no significant changes in the quantified data for the capital management items, as previously disclosed in the 2023 Consolidated Financial Statements. Please refer to Note 6 (XXVI) of the 2023 Consolidated Financial Statements for the relevant information.

(XXVI) Non-cash transactions in financing activities

The Consolidated Companies' non-cash transaction financing activities from January 1 to June 30, 2024 and 2023:

1. For right-of-use assets acquired under leases, please refer to Note 6 (VIII).

(XXVII)Changes in liabilities from financing activities

Adjustment of liabilities from financing activities:

				No	n-cash Transactio	ons	
		2024.1.1	Cash Flow	New Lease	Lease Modifications	Exchange Rate Changes	2024.6.30
Short-term loans	\$	91,565	226,422	-	-	-	317,987
Long-term loans		12,357	(12,651)	-	-	294	-
Lease liabilities		540,819	(36,047)	111,403	(13,773)	-	602,402
Guarantee deposits							
received		211	(160)	-		-	51
Total liabilities from	1						
financing							
activities	\$	644,952	177,564	111,403	(13,773)	294	920,440
				Noi	n-cash Transactio	ons	
		2022 1 1		N. I	Lease	Exchange Rate	2022 (20
C1 () 1	\$	2023.1.1	Cash Flow	New Lease	Modifications	Changes	2023.6.30
Short-term loans	\$	495,332	(413,767)	-	-	-	81,565
Long-term loans Lease liabilities		12,552	-	-	-	567	13,119 508,936
Guarantee deposits		526,590	(35,212)	17,795	(237)	-	508,950
received		51	-	-	-	-	51
Total liabilities from	1 —						
financing activities	<u>\$</u>	1,034,525	(448,979)	17,795	(237)	567	603,671

VII. Related Party Transactions

(I) The parent company and the ultimate controller are different entities, one of them has prepared Consolidated Financial Statements for public dissemination.

Hi-Clearance Investment Inc. holds 14.64% of the Consolidated Companies' outstanding common shares. While the shareholding does not exceed 50%, it gained control over the financial and operational aspects of the Consolidated Companies on June 2, 2016, and is regarded as the parent company. Collins Co., Ltd. is the ultimate controlling entity of the Group affiliated with the Consolidated Companies. Collins Co., Ltd. has prepared Consolidated Financial Statements for public dissemination.

(II) Names and relations of related parties

Related parties that had transactions with the Consolidated Companies during the period covered in the Consolidated Financial Statements:

Related Party	Relationship with the Consolidated Companies
Collins Co., Ltd.	Ultimate controller of the Consolidated Companies
QSC Corp.	Affiliate of the Consolidated Companies
WS Far IR Medical Technology Co., Ltd.	Affiliate of the Consolidated Companies
Yi Sheng Medical Care Co., Ltd.	Substantive related party of the Consolidated Companies
Xing Tian Medical Care Co., Ltd.	Substantive related party of the Consolidated Companies

(III) Significant transactions with related parties

1. Operating revenue

Sales to related parties and their outstanding balances:

_		Sale	s		Receivable	es from Relate	d Parties
	il to June 2024	April to June 2023	January to June 2024	January to June 2023	2024.6.30	2023.12.31	2023.6.30
Substantive related party: Yi Sheng Medical Care Co.,							
· · · · · · · · · · · · · · · · · · ·	\$ 48,134	87,811	100,492	176,057	50,858	72,017	92,728
Ltd.	12,581	2,339	29,665	16,442	20,712	13,063	11,554
5	\$ 60,715	90,150	130,157	192,499	71,570	85,080	104,282

Prices of goods sold to related parties are based on mutual agreement, and terms of payment are not significantly different from those of normal sales. Additionally, commissions are paid based on sales amounts. The commission expenses and payment terms for substantive related parties are agreed upon by both parties. For the periods from April 1 to June 30, 2024 and 2023, and from January 1 to June 30, 2024 and 2023, the commission amounts were NT\$4,075 thousand, NT\$1,928 thousand, NT\$9,147 thousand, and NT\$6,727 thousand, respectively. As of June 30, 2024, December 31, 2023, and June 30, 2023, NT\$4,553 thousand, NT\$4,665 thousand, and NT\$2,282 thousand remain unpaid and are recorded under "Other Payables - Related Parties".

2. Purchases

Purchases of the Consolidated Companies from related parties and their outstanding balances:

			Purcha		Payables to Related Parties			
		April to June 2024	April to June 2023	January to June 2024	January to June 2023	2024.6.30	2023.12.31	2023.6.30
Associate Substantive relate party: Yi Shen Medical Care O	g	629	1,327	2,336	2,414	2,293	2,282	1,873
Ltd.		-	(26)	-	(23)	-	-	-
	\$	629	1,301	2,336	2,391	2,293	2,282	1,873

The Consolidated Companies acquired the products from related parties without comparing the specifications with other suppliers, leading to a lack of price comparison. The payment terms are set at net 30-120 days.

3. Leases

Rental income from leasing office space to related parties (classified under "Other income") and its outstanding balance:

			Rental	Income			Receivab	les from Relate	ed Parties	
	April to 202		April to June 2023	January to June 2024	•	January to June 2023		2024.6.30	2023.12.31	2023.6.30
Associate	\$	15	15	5 2	29	2	9	-	-	-

4. Labor expenses

Amounts and outstanding balances for management services provided by related parties to the Consolidated Companies (recorded under "Operating expenses"):

		Amount of Tr	ansaction		Other Pay	yables to Related	Parties
	April to June 2024	April to June 2023	January to June 2024	January to June 2023	2024.6.30	2023.12.31	2023.6.30
Parent Company: Collins Co., Ltd. S	2,400	2,400	4,800	4,800	4,800	10,000	4,800

(IV) Major senior management personnel transactions

Major senior management personnel remuneration:

	Ар	ril to June 2024	April to June 2023	January to June 2024	January to June 2023
Short-term					
employee benefits	\$	13,869	11,884	27,209	23,854

VIII. Pledged Assets

(I) Carrying values of assets pledged by the Consolidated Companies:

Asset Name	Collateral Pledged	20	24.6.30	2023.12.31	2023.6.30
Restricted bank deposits (listed under Other Financial Assets - Current)	Performance guarantee/letter of credit limit	\$	57,261	58,895	50,402

Asset Name	Collateral Pledged	202	24.6.30	2023.12.31	2023.6.30
Land	Letter of credit limit/bank loan limit		107,873	107,873	107,873
Building and construction	Letter of credit limit/bank loan limit		51,342	52,134	52,926
		\$	216,476	218,902	211,201

(II) As of June 30, 2024, December 31, 2023, and June 30, 2023, the Consolidated Companies have opened forward letters of credit amounting to NT\$436,837 thousand, NT\$459,066 thousand, and NT\$466,578 thousand, respectively, and have used bills for collection deposited in banks in the amounts of NT\$187,438 thousand, NT\$220,652 thousand, and NT\$169,329 thousand, respectively, as collateral for 10-20% of the forward letters of credit.

IX. Significant Contingent Liabilities and Unrecognized Contract Commitments

	2024.6.30	2023.12.31	2023.6.30
Unused balance of issued letters of credit <u>\$</u>	183,177	213,055	204,987
Unrecognized contractual commitments			
for acquisition of property, plant and			
equipment <u>§</u>	6,062	12,036	4,895

X. Significant Disaster Loss: None.

XI. Significant Events after the Balance Sheet Date: None.

XII. Others

(I) Employee benefits, depreciation and amortization expenses by function:

Functions	Apr	il to June 2	024	Арі	ril to June 2	2023
	Operation	Operation	Total	Operation	Operation	Total
Characteristics	Costs	Expenses	IUtai	Costs	Expenses	Total
Employee benefits						
Salary expenses	16,944	96,161	113,105	16,509	100,802	117,311
Labor and health	1,279	5,899	7,178	1,273	5,576	6,849
insurance						
Pension expenses	734	4,633	5,367	733	4,433	5,166
Other employee	462	2,063	2,525	391	1,944	2,335
benefits						
Depreciation expenses	35,766	5,553	41,319	33,176	4,732	37,908
Amortization expenses	-	4,140	4,140	-	3,396	3,396

Functions	Janua	ry to June	2024	January to June 2023				
	Operation	Operation Operation		Operation	Operation	Total		
Characteristics	Costs	Expenses	Total	Costs	Expenses	Total		
Employee benefits								
Salary expenses	32,960	183,510	216,470	32,515	186,381	218,896		
Labor and health	2,768	13,369	16,137	2,785	12,794	15,579		
insurance								
Pension expenses	1,467	9,105	10,572	1,468	8,755	10,223		
Other employee	859	3,918	4,777	794	3,736	4,530		
benefits								
Depreciation expenses	68,617	11,001	79,618	65,688	9,315	75,003		
Amortization expenses	-	8,280	8,280	-	6,792	6,792		

(II) Seasonality of operations:

The operations of the Consolidated Companies are not affected by seasonal or cyclical factors.

XIII. Supplementary Disclosures

(I) Information on Significant Transactions

The Consolidated Companies are required to disclose the following significant transaction information from January 1 to June 30, 2024, in compliance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers:

- 1. Loans provided for others: None.
- 2. Endorsements/guarantees provided for others:

Number	Company of Endorser/ Guarantor	Endorsed and Part Name of Company	ties	Limit on Endorsements/ Guarantees Provided for a Single Entity		Ending Endorsement/ Guarantee Balance	Actual Amount Drawn	Guarantees Collateralized	Ratio of Accumulated Endorsements/ Guarantees to Net Worth per Latest Financial Statements	Endorsement/ Guarantee Ceiling	Endorsements/ Guarantees Provided by Parent for Subsidiary	Endorsements/ Guarantees Provided by Subsidiary for Parent	Endorsements/ Guarantees Provided for Subsidiary in Mainland China
0		Sin Hwa Co.,	2	1,439,791	50,000	50,000	-	Promissory note	1.74%	1,439,791	Y	N	N
0	Company The Company	Ltd. HC-Healthcare Co., Ltd.	2	1,439,791	120,000	120,000		50,000 Promissory note 120,000	4.17%	1,439,791	Y	Ν	Ν

Note 1: The total endorsement/guarantee amount is limited to 50% of the net worth indicated in the Consolidated Companies' previous financial statements. The endorsement/guarantee amount to a single enterprise is limited to 50% of the net worth indicated in the previous period's financial statements.

- Note 2: The relationships between endorsers/guarantors and endorsees/guarantees are categorized into the following 7 types. Please specify the type:
 - (1) Companies engaged in business transactions.
 - (2) Companies in which the Company directly and indirectly holds more than 50% of the voting shares.
 - (3) A company that directly and indirectly holds more than 50% of the voting shares in the Company.
 - (4) Companies in which the Company directly or indirectly holds at least 90% of the voting shares.
 - (5) Companies that are in the same industry that have mutual endorsements/guarantees in favor of each other, or those that enter in contracts with such provisions, for the purpose of contracting works.

- (6) A company that is endorsed/guaranteed by all of the contributing shareholders in proportion with their shareholding ratios due to a joint investment relationship.
- (7) Companies in the same industry who participate in the joint guarantee of performance for pre-sale house sales contracts in compliance with the Consumer Protection Act.
- Note 3: The above transactions were eliminated in the preparation of the Consolidated Financial Statements.
- 3. Securities held at end of period (excluding investments in subsidiaries, associates, and interests in joint ventures):

а и пли		Relationship	itionship	Ending Balance					
Securities Holding Company	Type and Name of Securities	with Issuer of Securities	Ledger Account	Number of Shares/Units	Carrying Amount	Shareholding Ratio	Fair Value	Remark	
	Fuh Hwa You Li	-	Financial assets at	742	10,310	- %	10,310		
Investment Co., Ltd.	Money Market Fund		fair value through profit or loss - current						
Sin Hwa	SinoPac Global Multi	-	Financial assets at	1,000	11,392	- %	11,392		
Investment Co.,	Income Fund TWD		fair value through						
Ltd.	Acc		profit or loss - current						
XinFu Healthcare	Fuh Hwa You Li	-	Financial assets at	2,264	31,465	- %	31,465		
Corp.	Money Market		fair value through						
Ĩ	Fund		profit or loss - current						
The Company	Taiwan Depository &	-	Financial assets at	1	268	- %	268		
	Clearing		fair value through						
	Corporation		other						
	-		comprehensive						
			income -						
			non-current						
The Company	EPED Inc.		Financial assets at	1,406	45,000	4.87%	45,000		
			fair value through						
			other						
			comprehensive						
			income -						
			non-current						
Taicha Medical	Shanghai Shen Shang	-	Financial assets at	-	-	6.20%	-		
Corp. (Shanghai)	Technology Co.,		fair value through						
	Ltd.		other						
			comprehensive						
			income -						
			non-current						

Unit: thousand shares/thousand units

- 4. Accumulated purchase or sale of the same securities amounting to NT\$300 million or 20% of paid-in capital or more: None.
- 5. Acquisition of property amounting to NT\$300 million or 20% of paid-in capital or more:

Unit: NT\$ thousand

Acquired Company	Name of Property		Amount of Transaction		Counterparty	Relationship	ation on Prior Counterparty Relationship with the Issuer	Is Relate	d	Basis or Reference for Price	Purpose of Acquisition and Usage Status	Other Agreed
The Company	Land	2024.4.16	206,180	206,180	Chiayi County	Non-related			-	Tender	Warehouse	None
					Government	party					land	

On April 16, 2024, the Consolidated Companies acquired the "Chiayi Interchange Special Zone Goods Transfer Center Area Land Readjustment Area," as announced by the Chiayi County Government, through a public bidding process. The land is intended for a warehouse expansion plan. The total transaction amount was NT\$206,180 thousand, and the land payment has been completed. The relevant ownership registration procedures are in progress and are recorded under "Other Non-current Assets".

- 6. Disposal of property amounting to NT\$300 million or 20% of paid-in capital or more: None.
- 7. Purchases from or sales to related parties amounting to at least NT\$100 million or 20% of the paid-in capital:

		y Relationship	Transaction Situation					l Transaction and Reasons	Notes and Receivable		
Importing (Selling) Company	Counterparty		Purchases (Sales)		Percentage of Total Purchases (Sales)	Credit	Unit Price	Credit Period		Percentage of Notes and Accounts Receivable (Payable)	Remark
The Company	Yi Sheng Medical Care Co., Ltd.	Substantive related party of the Company	Sales	100,492	(5.49)%	Net 90 EOM	-	-	50,858	4.46%	

Unit: NT\$ thousand

- 8. Receivables from related parties amounting to NT\$100 million or 20% of paid-up capital or more: None.
- 9. Derivatives transactions: Please refer to Note 6 (II).
- 10. Business relationships and significant transactions between the parent company and subsidiaries:

				,	Trading Activi	ities in 2024	
Number	Company	Counterparty	Relationship	Ledger Account	Amount	Transaction Term	Percentage of Consolidated Total Revenue or Total Assets
0	The Company	Renalysis Medical Care	1	Sales	1,833	Net 120 EOM	0.09%
0	The Company	Co., Ltd. Renalysis Medical Care Co., Ltd.	1	Accounts receivable	1,485	Net 120 EOM	0.03%
0	The Company	Renalysis Medical Care Co., Ltd.	1	Rental Income	1,127	Pursuant to the terms of the contract	0.05%
0	The Company	Sin Hwa Co., Ltd.	1	Purchases	2,613	Net 30 EOM	0.13%
0	The Company	Sin Hwa Co., Ltd.	1	Accounts payable	1,056	Net 30 EOM	0.02%
0	The Company	HMI company	1	Sales	8,015	Net 270 EOM	0.39%
0	The Company	HMI company	1	Accounts receivable	8,015	Net 270 EOM	0.16%
0	The Company	HC-Healthcare Co., Ltd.	1	Accounts receivable	6,694	Net 120 EOM	0.13%
0	The Company	HC-Healthcare Co., Ltd.	1	Sales	10,312	Net 120 EOM	0.50%
0	The Company	HC-Healthcare Co., Ltd.	1	Other expenses	1,007	Net 120 EOM	0.05%

- Note 1: The number should be filled in using the following method:
 - 1. 0 represents the parent company.
 - 2. Subsidiaries are sorted in a numerical order starting from 1.
- Note 2: Types of relationships with counterparties are indicated as follows:
 - 1. The parent company to subsidiaries.
 - 2. Subsidiaries to the parent company.
 - 3. Subsidiaries to subsidiaries.
- Note 3: The report only provides one-sided information on sales, revenue, and accounts receivable, without any additional details on purchases, expenses, and accounts payable.
- Note 4: Transactions with a value of NT\$1 million or more should be disclosed.
- Note 5: The above transactions were eliminated in the preparation of the Consolidated Financial Statements.
- (II) Information on Invested Companies:

Details regarding the Consolidated Companies' investments from January 1 to June 30, 2024 (excluding investments in mainland China):

Unit: NT\$ thousand/thousand s	shares
--------------------------------	--------

				Initial In Amo			Ending Balanc	e	D 5/7 6	.	
Name of Investor	Name of Investee	Location	Main Business Activities	Ending Balance for the Current Period	End of Previous Year	Shares	Shareholding	Carrying Amount	Profit/Loss of Investee for the Period		Remark
The Company	Succeed Agents	U	Financial holding	49,649	11,918	1,575	100.00%	86,633	(107)	(107)	(Note 1)
The Company	Limited (B.V.I.) Renalysis Medical Care Co., Ltd.	Islands. Sanchong District, New Taipei City	and investment Medical management consulting	165,037	165,037	10,000	100.00%	238,717	31,219	31,218	(Note 1)
The Company	XinFu Healthcare Corp.	Sanchong District, New Taipei City	services Medical management consulting services	50,000	50,000	5,000	100.00%	53,017	1,284	1,284	(Note 1)
The Company	Sin Hwa Co., Ltd.	Sanchong District, New Taipei City	Medical equipment trade	100,000	100,000	10,000	100.00%	111,224	6,660	6,660	(Note 1)
The Company	Sin Hwa Investment Co., Ltd.	Sanchong District, New Taipei City	Financial holding and investment	80,000	80,000	8,000	100.00%	82,896	5,199	5,199	(Note 1)
The Company	HC-Healthcare Co., Ltd.	Sanchong District, New Taipei City	Medical management consulting services	118,919	118,919	36,517	100.00%	136,808	1,116	1,411	(Note 1)
The Company	WS Far IR Medical Technology Co., Ltd.	Xindian District, New Taipei City	Medical equipment manufacturing and sales	63,600	63,600	600	30.00%	62,435	13,178	3,953	
Sin Hwa Investment Co., Ltd.	QSC Corp.	Sanchong District, New Taipei City	Medical equipment manufacturing and sales	60,000	60,000	6,000	20.00%	57,905	21,358	4,271	
Succeed Agents Limited (B.V.I.)	Moral Well Co., Ltd.	Apia Samoa	Financial holding and investment	58,973	58,973	2,000	100.00%	32,188	(244)	(244)	(Note 1)
Succeed Agents Limited (B.V.I.)	PT Hiclearance Medical Indonesia	Republic of Indonesia	Medical equipment trade	60,540	23,694	2,000	100.00%	51,572	120	120	(Note 1)

Note 1: The above transactions were eliminated in the preparation of the Consolidated Financial Statements.

(III) Information on Investments in Mainland China:

1. Information on investments in mainland China:

Unit: US\$ thousand/NT\$ thousand/RMB thousand

Investee Company	Main Business Activities	Paid-in Capital	Method of Investments (Note 1)	Accumulated Amount of Investments Remitted from Taiwan at Beginning of Period	Inve Rem Repatria Po	ount of stments itted or ated for the eriod Repatriated	Remitted from Taiwan at End	Period	Company's Direct or Indirect Ownership	Recognized for the	End-of-period Investment Book Value	Accumulated Investment Income Repatriated at End of Period
	International	64,900	(III)	20,785	-	-	20,785	(244)	100.00%	(244)	32,178	-
Medical	trade and	(USD2,000)		(USD700)			(USD700)	(USD(8))		(USD(8))	· · · · · · · · · · · · · · · · · · ·	
Corp.	re-export	(Note 3)								(Note 2)	(Note 2)	
(Shanghai)	trade											
Shanghai	Medical	17,935	(III)	-	-	-	-	-	6.20%	-		-
Shen	software	(RMB4,034)										
Shang	developm											
Technolog	ent and											
y Co., Ltd.	technical											
(Note 4)	services											

Note 1: Methods of investment are divided into the following three types:

- (I) Direct investment in mainland China.
- (II) Reinvestment in mainland China via a third-party company located in a different region.
- (III) Others.
- Note 2: The above transactions were eliminated in the preparation of the Consolidated Financial Statements.
- Note 3: A portion of the investment funds came from MW's own capital and was not transferred from Taiwan.
- Note 4: The investment amount was established by Taicha Medical Corp.'s own funds, not transferred from Taiwan, and full impairment was recorded in 2022. The transaction was not eliminated in the preparation of the Consolidated Financial Statements.
- 2. Limit for investment to mainland China:

Accumulated Amount of Investments Remitted from	Amount of Investments Authorized by Investment	Investments Stipulated
Taiwan to Mainland China at End of Period (Note 1)	Commission, M.O.E.A. (Note 2)	by Investment Commission, M.O.E.A.
23,768	68,145	1,727,749
(US\$800 thousand)	(US\$2,100 thousand)	

- Note 1: Xing Tai International Trading (Shanghai) Co., Ltd. was sold in the first quarter of 2013, however, the payment has not yet been remitted to Taiwan. Therefore, the Consolidated Companies have accumulated a remittance amount of US\$100 thousand, equivalent to NT\$2,983 thousand, which still needs to be accounted for in line with regulations of the Investment Commission.
- Note 2: Accumulated amount of investments remitted from Taiwan to mainland China at end of period was calculated based on historical exchange rates.
- 3. Information on significant transactions:

For details regarding significant transactions between the Consolidated Companies and their investees in Mainland China from January 1 to June 30, 2024 (eliminated at the time of preparation of the Consolidated Financial Statements), please refer to the section "Information on Significant Transactions".

(IV) Information on Major Shareholders:

Unit: shares

Shareholding Name of Major Shareholders	Shares	Percentage of Ownership
Hi-Clearance Investment Inc.	6,519,991	14.64%
LCL Capital Inc.	3,531,994	7.93%
Collins Co., Ltd.	2,385,536	5.35%

Note:

- (1) The major shareholders in this table are shareholders holding more than 5% of the ordinary and preference shares that have completed delivery without physical registration (including treasury shares) on the last business day of each quarter calculated by the Taiwan Depository & Clearing Corporation. Share capital indicated in the Company's financial report may differ from the actual number of shares that have been issued and delivered by the Company without physical registration, as a result of different basis of preparation.
- (2) If a shareholder delivers its shareholding information to the trust, the aforesaid information shall be disclosed by the individual trustee who opened the trust account. Please refer to MOPS for information on shareholders who declare themselves to be insiders holding more than 10% of shares in accordance with the Securities and Exchange Act, and their shareholdings including their shareholdings plus their delivery of trust and shares with the right to make decisions on trust property.

XIV. Segment Information

Information and adjustments pertain to the business segments of the Consolidated Companies:

	April to June 2024							
	Н	emodialysis Division	Other Divisions	Adjustment and Elimination	Total			
Revenue:								
Revenue from external customers	\$	706,428	390,558	-	1,096,986			
Intersegment revenue		-	-	-				
Total revenue	<u>\$</u>	706,428	390,558	-	<u>1,096,986</u>			
Reportable segment profit or loss	<u>\$</u>	82,876	37,323	-	120,199			
Reportable segment assets (Note)	\$	-	-	-				

	April to June 2023						
	Н	emodialysis Division	Other Divisions	Adjustment and Elimination	Total		
Revenue:							
Revenue from external customers	\$	706,275	249,925	-	956,200		
Intersegment revenue		-		-			
Total revenue	<u>\$</u>	706,275	249,925	_	956,200		
Reportable segment profit or loss	<u>\$</u>	63,042	31,698		94,740		
Reportable segment assets (Note)	<u>\$</u>	-					
			January to	June 2024			

	January to June 2024							
	Hemodialysis Division	s Other Divisions	Adjustment and Elimination	Total				
Revenue:								
Revenue from external customers	\$ 1,423,668	638,161	-	2,061,829				
Intersegment revenue			-					
Total revenue	<u>\$ 1,423,668</u>	638,161		2,061,829				
Reportable segment profit or loss	<u>\$ 165,648</u>	60,117	-	225,765				
Reportable segment assets (Note)	<u>s -</u>	-	-					

	January to June 2023							
	Hemodialysis Division	Other Divisions	Adjustment and Elimination	Total				
Revenue:								
Revenue from external customers	\$ 1,409,635	519,544	-	1,929,179				
Intersegment revenue			-					
Total revenue	<u>\$ 1,409,635</u>	519,544		<u>1,929,179</u>				
Reportable segment profit or loss	<u>\$ 141,817</u>	52,414	_	<u> </u>				
Reportable segment assets (Note)	<u>s -</u>		-					

(Note) The disclosed amount for the Consolidated Companies is 0 because the measurement of total divisional assets was not provided to the operational decision-makers.